Molecular Cancer

OCT 17, 2026 · JOURNAL ARTICLE

circRAB6A-encoded KAPEP relieves PTPN6-mediated restraint on JAK-STAT signaling to drive KRAS-mutant colorectal cancer progression

Molecular Cancer

Despite advances in targeted therapy, effective treatment of KRAS-mutant colorectal cancer (CRC) remains challenging. Although circular RNAs (circRNAs) have emerged as important re

OCT 16, 2026 · JOURNAL ARTICLE

The PD-1/PD-L1 axis in cancer: from immune evasion mechanisms to next-generation therapeutics

Molecular Cancer

Immune checkpoint blockade directed against the programmed cell death protein 1 (PD-1) receptor and its ligand PD-L1 has markedly transformed cancer therapy, producing sustained cl

OCT 14, 2026 · JOURNAL ARTICLE

It takes two to tango: the intersection of deubiquitinases and m6A modification in cancer

Molecular Cancer

The dynamic and reversible N 6 -methyladenosine (m 6 A) RNA modification has emerged as a pivotal layer of epitranscriptomic regulation in cancer, governing RNA metabolism and func

OCT 1, 2026 · JOURNAL ARTICLE

Heterogeneity of cancer-associated fibroblasts in tumor metastasis: mechanisms and precision therapeutic strategies

Molecular Cancer

Cancer-associated fibroblasts (CAFs) are key regulators of the tumor microenvironment (TME) and influence multiple stages of tumor metastasis through extracellular matrix (ECM) rem

SEP 22, 2026 · JOURNAL ARTICLE

Patient-derived organoids for modeling therapy tolerance, persistence, and resistance in cancer

Molecular Cancer

Therapy resistance remains a major obstacle to durable cancer control. Across cytotoxic chemotherapy, molecularly targeted therapy, immunotherapy, endocrine therapy, and cellular t

SEP 22, 2026 · JOURNAL ARTICLE

Dysfunction of CD58 in tumor immune evasion: from mechanistic regulation to therapeutic resistance

Molecular Cancer

Abstract CD58, the primary ligand of the co-stimulatory receptor CD2, plays a crucial role in the formation of the immunological synapse (IS) and the initiation of antitumor immuni

SEP 22, 2026 · JOURNAL ARTICLE

Targeting ADAR1 reprograms cold tumors to hot and enhances immunotherapy in bladder cancer

Molecular Cancer

Despite significant advances in immunotherapy for certain solid tumors, bladder cancer (BCa) exhibits limited responsiveness, primarily due to its highly immunosuppressive “cold” t

SEP 17, 2026 · JOURNAL ARTICLE

Extrachromosomal DNA as a platform for epigenetic reprogramming in cancer

Molecular Cancer

Extrachromosomal DNA (ecDNA) has emerged as a major contributor to cancer aggressiveness, yet its role extends far beyond its classical definition as a vehicle for oncogene amplifi